You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.